The first formal classification of chronic myeloid neoplasms is credited to William Dameshek,
who in 1951 described the concept of “myeloproliferative disorders (MPD)” by grouping …

The approach to a patient with erythrocytosis is greatly simplified by assessing the clonality
of the process upfront. In this regard, there has been a dramatic shift toward genetic testing …

Chromosomal abnormalities are frequent in myeloid malignancies, but in most cases of
myelodysplasia (MDS) and myeloproliferative neoplasms (MPN), underlying pathogenic …

Recent evidence has demonstrated that acquired uniparental disomy (aUPD) is a novel
mechanism by which pathogenetic mutations in cancer may be reduced to homozygosity. To …

8 Roman-Gomez J, Jimenez-Velasco A, Barrios M, Prosper F, Heiniger A, Torres A et al.
Poor prognosis in acute lymphoblastic leukemia may relate to promoter hypermethylation of …

TET2 (TET oncogene family member 2) is a candidate tumor suppressor gene located at
chromosome 4q24, and was recently reported to be mutated in∼ 14% of patients with …

Somatic mutations in Janus kinase 2 (JAK2), including JAK2V617F, result in dysregulated
JAK-signal transducer and activator transcription (STAT) signaling, which is implicated in …

Cytoreductive therapy in systemic mastocytosis (SM) includes several drugs whose
individual merit has not been well characterized. We retrospectively studied 108 Mayo Clinic …

Abstract The mutant JAK2V617F tyrosine kinase (TK) is present in the majority of patients
with BCR-ABL–negative myeloproliferative neoplasms (MPNs). JAK2V617F activates …

The 2008 WHO classification system for hematological malignancies is comprehensive and
includes histology and genetic information. Myeloid neoplasms are now classified into five …